Enforcement and litigation
Does being terminally ill create an automatic legal right to unapproved treatments?
Plain English first, then the primary source. Education, not legal advice.
Interpretation
In short: courts have declined to create a general right of access to unapproved treatments. Access questions run through regulatory pathways.
Plain English
In United States v. Rutherford, the Supreme Court considered whether the FD&C Act's safety and effectiveness requirements applied to a drug (Laetrile) sought by terminally ill cancer patients, and rejected the argument that a terminally ill patient's condition removes the drug from the statute's safety and effectiveness requirements. The Court held that the statutory language did not carve out a terminal-illness exception.
This case illustrates that sympathetic facts, including serious or terminal illness, do not automatically override the FD&C Act's structure. Congress and FDA have since created narrower pathways, such as expanded access, but these are specific regulatory mechanisms with their own conditions, not a general legal exception created by the patient's diagnosis alone.
Why it matters
- This case is commonly cited in discussions of a 'right to try' unapproved treatments and shows how courts have approached the tension between patient autonomy and drug safety law.
Where the answer becomes fact-specific
The Foundation does not manufacture legal conclusions. These points change the analysis and may require qualified regulatory counsel.
- Later statutory developments, including state and federal 'right to try' laws enacted after this decision, may affect the analysis in specific situations and should be checked separately.
View the source
- United States v. Rutherford, 442 U.S. 544 (1979), 442 U.S. 544 (1979)